Thor Medical signs agreement for supply of Pb-212 for pre-clinical use with globally leading pharmaceutical company

22 Nov 2024 07:45 CET

22.11.2024 07:45:01 CET | Thor Medical ASA | Inside information

Oslo, 22 November, 2024: Thor Medical, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, has signed an
agreement with a globally leading pharmaceutical company for the supply of
Pb-212 alpha-emitters for use in pre-clinical studies.

Thor Medical will supply the Pb-212 isotopes from its newly established Herøya
pilot facilities. Pb-212, or Lead-212, is a therapeutic radioisotope for
precision cancer treatment with a short half-life, derived from the Thorium-228
decay. Deliveries will commence in 2025 under a three-year supply agreement.

"While the volumes under this agreement reflect that the intended use is for
pre-clinical studies and evaluation and not commercial scale, this agreement
highlights our ability to establish contracts with major players in the
pharmaceutical industry, demonstrating trust in our capabilities to deliver the
high-quality radioisotopes required to enable highly promising next-generation
precision cancer treatments," says Jasper Kurth, CEO of Thor Medical.

This supply agreement adds to recent milestones including the signing of a
strategic long-term supply agreement of Thorium-228 to ARTBIO, and the recent
first shipment of product samples from the Herøya pilot facility to another
undisclosed potential customer.

On 25 November, Thor Medical will host a Capital Markets Update in Stockholm,
featuring presentations from both Thor Medical and ARTBIO.





CONTACT

Thor Medical Brede Ellingsæter, CFO, +47 472 38 440

brede.ellingseter@thormedical.com - brede.ellingseter@thormedical.no





ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol 'TRMED'.





IMPORTANT INFORMATION

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock
exchange announcement was published by Brede Ellingsæter, CFO, Thor Medical ASA,
at the time and date stated above in this announcement.

This release contains forward -looking information and statements relating to
the business, performance, and matters that may impact the results of Thor
Medical. Forward-looking statements are statements that are not historical facts
and may be identified by words such as "aims," "anticipates," "believes,"
"estimates," "expects," "foresees," "intends," "plans," "predicts," "projects,"
"targets," "potential," and similar expressions. Such forward-looking statements
are based on current expectations, estimates, and projections, reflect current
views concerning future events, and are subject to risks, uncertainties, and
assumptions, and may be subject to change without notice. Forward-looking
statements are not guarantees of any future performance, and risks,
uncertainties, and other important factors could cause the actual business,
performance, results, or the industry and markets in which Thor Medical operates
to differ materially from the statements expressed or implied in this release by
such forward-looking statements. No representation is made that any of these
forward-looking statements or forecasts will come to pass or that any forecasted
performance, capacities, or results will be achieved, and you are cautioned not
to place any undue reliance on any forward-looking statements.

This release is for information purposes only and is not to be relied upon in
substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18332253/5327/Download%20announce
ment%20as%20PDF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

632942_Download announcement as PDF.pdf